A Phase IIb, Randomized, Observer-Masked, Placebo- and Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-126 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Santen Inc.
- Enrollment
- 241
- Locations
- 17
- Primary Endpoint
- Intraocular Pressure in the Study Eye at Month 3
Study Overview
Brief Summary
Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for reducing the risk of glaucomatous visual field loss.
This study is being conducted to determine how well DE-126 ophthalmic solution works (efficacy) in safely lowering IOP when dosed as topical eyedrops. This study will evaluate the safety and efficacy of four (4) concentrations of DE-126, when compared with latanoprost (0.005%) eye drops in patients with primary open-angle glaucoma or ocular hypertension.
The IOP will be measured at 3 different times throughout the day, over 6 total visits during a 3-month treatment period (with up to 4 extra weeks observation if the patient must stop taking current eye drops to lower IOP). Safety assessments will be done throughout the study, including ocular signs and symptoms, vital signs, and clinical laboratory tests. While the most important time-point to measure IOP in this study and evaluate efficacy will be at the final study visit (month 3), IOP values will also be evaluated at other visits throughout the 3-month treatment period.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Provide signed written informed consent
- •Diagnosis of POAG or OHT in both eyes
- •Qualifying corrected visual acuity in each eye
- •Qualifying central corneal thickness in each eye
- •Qualifying Day 1 IOP measurement at 3 time-points in both eyes
- •Qualifying Anterior chamber angle
Exclusion Criteria
- •History of ocular surgery specifically intended to lower IOP
- •Subjects who cannot safely discontinue use of ocular hypotensive medications during the wait/washout period
- •Advanced glaucoma in either eye
- •Any corneal abnormality or other condition interfering with or preventing reliable Goldmann applanation tonometry
- •Any ocular surgery or ocular laser treatment within 90 days prior to Visit 1 (Screening) and throughout the study in either eye
- •Females who are pregnant, nursing, or planning a pregnancy
Arms & Interventions
Ultra-low dose 0.0005% DE-126
Intervention: Topical ultra-low dose of DE-126 Ophthalmic Solution (Drug)
Placebo (Vehicle of DE-126) followed by high dose of DE-126
Intervention: Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution (Drug)
Low dose 0.001% DE-126
Intervention: Topical low dose of DE-126 Ophthalmic Solution (Drug)
Medium dose 0.002% DE-126
Intervention: Topical medium dose of DE-126 Ophthalmic Solution (Drug)
High dose 0.003% DE-126
Intervention: Topical high dose of DE-126 Ophthalmic Solution (Drug)
0.005% Latanoprost
Intervention: 0.005% Latanoprost Ophthalmic Solution (Drug)
Outcomes
Primary Outcomes
Intraocular Pressure in the Study Eye at Month 3
Time Frame: 9:00, 13:00 and 17:00 at Month 3
Intraocular Pressure (IOP),the fluid pressure inside the eye was measured by the Goldmann applanation tonometer in millimeters mercury (mmHg) at 3 time-points throughout the day.
Secondary Outcomes
- Intraocular Pressure in the Study Eye at Week 6(9:00, 13:00 and 17:00 at Week 6)
- Intraocular Pressure in the Study Eye at Week 1 and Week 2(9:00, 13:00 and 17:00 at Week 1 and Week 2)
- Mean Diurnal Intraocular Pressure in the Study Eye at Each Post-baseline Visit(Week 1, Week 2, Week 6 and Month 3.)
- Change From Baseline (CFB) in Mean Diurnal Intraocular Pressure in the Study Eye at Each Post-baseline Visit(Week 1, Week 2, Week 6 and Month 3.)
- Percent Change From Baseline (CFB) in Mean Diurnal Intraocular Pressure in the Study Eye at Each Post-baseline Visit(Week 1, Week 2, Week 6 and Month 3.)
- Change From Baseline (CFB) in Intraocular Pressure in the Study Eye at Three Time Points at Each Post-baseline Visit(9:00, 13:00 and 17:00 at Week 1, Week 2, Week 6 and Month 3.)
- Percent Change From Baseline (CFB) in Intraocular Pressure in the Study Eye at Three Time Points at Each Post-baseline Visit(9:00, 13:00 and 17:00 at Week 1, Week 2, Week 6 and Month 3.)
- Percentage of Subjects With Mean Diurnal Intraocular Pressure Reduction From Baseline ≥ 20%, 25% and 30% in the Study Eye at Each Post-baseline Visit(WeeK 1, Week 2, Week 6 and Month 3.)
- Percentage of Subjects With Mean Diurnal Intraocular Pressure ≤ 18 mmHg in the Study Eye at Each Post-baseline Visit(Week 1, Week 2, Week 6 and Month 3.)